Advances in treatment with induced pluripotent stem cells and somatic cell transdifferentiation for multiple sclerosis

LI Mei; XIE Chong; GUAN Yangtai

doi:10.12022/jnnr.2016-0026

PDF(1353 KB)

Journal of Neurology and Neurorehabilitation ›› 2016, Vol. 12 ›› Issue (1) : 24-28. DOI: 10.12022/jnnr.2016-0026

Review

Advances in treatment with induced pluripotent stem cells and somatic cell transdifferentiation for multiple sclerosis

LI Mei¹, XIE Chong¹, GUAN Yangtai^1,2

Author information +

History +

Abstract

Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of central nervous system and remains one of the major causes of disability in young adults. Conventional therapeutics can only prolong the remission duration, but do not cure it. Induced pluripotent stem cells (iPSCs) with the same totipotent differentiation as the stem cells have a broad prospect for application of cell replacement therapy in MS. Somatic cell reprogramming and transdifferentiating can shorten the time for generating oligodendrocyte cell lineage, as compared with the traditional method with iPSCs, which provides a new idea for the treatment of MS. With the improved efficiency and quality in obtaining neural stem cells and oligodendrocytes, it is possible to have a big achievement in cell therapy for MS.

Key words

Multiple sclerosis / Induced pluripotent stem cells / Transdifferentiation

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Mei, XIE Chong, GUAN Yangtai. Advances in treatment with induced pluripotent stem cells and somatic cell transdifferentiation for multiple sclerosis[J]. Journal of Neurology and Neurorehabilitation. 2016, 12(1): 24-28 https://doi.org/10.12022/jnnr.2016-0026

References

[1] et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria[J]. Ann Neurol, 2011, 69(2): 292-302.
[2] POSER C M, BRINAR V V. Diagnostic criteria for multiple sclerosis[J]. Clin Neurol Neurosurg, 2001, 103(1):1-11.
[3] POLMAN C H, REINGOLD S C, EDAN G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”[J]. Ann Neurol, 2005, 58(6):840-846.
[4] KHAN O A, TSELIS A C, KAMHOLZ J A, et al. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis[J]. Eur J Neurol, 2001, 8(2):141-148.
[5] SANDBERG-WOLLHEIM M, BEVER C, CARTER J, et al. Comparative tolerance of IFN beta-1α regimens in patients with relapsing multiple sclerosis. The EVIDENCE study[J]. J Neurol, 2005, 252(1):8-13.
[6] KAPPOS L, RADUE E W, O’CONNOR P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis[J]. N Engl J Med, 2010, 362(5):387-401.
[7] CALABRESI P A, RADUE E W, GOODIN D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2014, 13(6):545-556.
[8] MILLER D H, KHAN O A, SHEREMATA W A, et al. A controlled trial of natalizumab for relapsing multiple sclerosis[J]. N Engl J Med, 2003, 348(1):15-23.
[9] POLMAN C H, O’CONNOR P W, HAVRDOVA E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis[J]. N Engl J Med, 2006, 354(9):899-910.
[10] CHAHIN S, BALCER L J, MILLER D M, et al. Vision in a phase 3 trial of natalizumab for multiple sclerosis: relation to disability and quality of life[J]. J Neuroophthalmol, 2015, 35(1):6-11.
[11] TAKAHASHI K, YAMANAKA S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4):663-676.
[12] LATERZA C, MERLINI A, DE FEO D, et al. iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF[J]. Nat Commun, 2013(4):2597.
[13] WANG S, BATES J, LI X, et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination[J]. Cell Stem Cell, 2013, 12(2):252-264.
[14] AASEN T, RAYA A, BARRERO M J, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes[J]. Nat Biotechnol, 2008, 26(11):1276-1284.
[15] PARK I H, ZHAO R, WEST J A, et al. Reprogramming of human somatic cells to pluripotency with defined factors[J]. Nature, 2008, 451(7175):141-146.
[16] YU J, VODYANIK M A, SMUGA-OTTO K, et al. Induced pluripotent stem cell lines derived from human somatic cells[J]. Science, 2007, 318(5858):1917-1920.
[17] TOKUMOTO Y, OGAWA S, NAGAMUNE T, et al. Comparison of efficiency of terminal differentiation of oligodendrocytes from induced pluripotent stem cells versus embryonic stem cells in vitro[J]. J Biosci Bioeng, 2010, 109(6):622-628.
[18] OGAWA S, TOKUMOTO Y, MIYAKE J, et al. Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells[J]. In Vitro Cell Dev Biol Anim, 2011, 47(7):464-469.
[19] SONG B, SUN G, HERSZFELD D, et al. Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis[J]. Stem Cell Res, 2012, 8(2):259-273.
[20] PLUCHINO S, QUATTRINI A, BRAMBILLA E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis[J]. Nature, 2003, 422(6933):688-694.
[21] YANG J, YAN Y, CIRIC B, et al. Evaluation of bone marrow- and brain-derived neural stem cells in therapy of central nervous system autoimmunity[J]. Am J Pathol, 2010, 177(4):1989-2001.
[22] CZEPIEL M, BALASUBRAMANIYAN V, SCHAAFSMA W, et al. Differentiation of induced pluripotent stem cells into functional oligodendrocytes[J]. Glia, 2011, 59(6):882-892.
[23] POUYA A, SATARIAN L, KIANI S, et al. Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination[J]. PLoS One, 2011, 6(11):e27925.
[24] DOUVARAS P, WANG J, ZIMMER M, et al. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells[J]. Stem Cell Reports, 2014, 3(2):250-259.
[25] TAMAKI S, TOKUMOTO Y. Overexpression of cyclin dependent kinase inhibitor P27/Kip1 increases oligodendrocyte differentiation from induced pluripotent stem cells[J]. In Vitro Cell Dev Biol Anim, 2014, 50(8):778-785.
[26] CZEPIEL M, LEICHER L, BECKER K, et al. Overexpression of polysialylated neural cell adhesion molecule improves the migration capacity of induced pluripotent stem cell-derived oligodendrocyte precursors[J]. Stem Cells Transl Med, 2014, 3(9):1100-1109.
[27] KIM J, EFE J A, ZHU S, et al. Direct reprogramming of mouse fibroblasts to neural progenitors[J]. Proc Natl Acad Sci U S A, 2011, 108(19):7838-7843.
[28] THIER M, WORSDORFER P, LAKES Y B, et al. Direct conversion of fibroblasts into stably expandable neural stem cells[J]. Cell Stem Cell, 2012, 10(4):473-479.
[29] RING K L, TONG L M, BALESTRA M E, et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor[J]. Cell Stem Cell, 2012, 11(1):100-109.
[30] LUJAN E, CHANDA S, AHLENIUS H, et al. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells[J]. Proc Natl Acad Sci U S A, 2012, 109(7):2527-2532.
[31] HAN Y C, LIM Y, DUFFIELDL M D, et al. Direct reprogramming of mouse fibroblasts to neural stem cells by small molecules[J]. Stem Cells Int, 2016:4304916.
[32] NAJM F J, LAGER A M, ZAREMBA A, et al. Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells[J]. Nat Biotechnol, 2013, 31(5):426-433.
[33] YANG N, ZUCHERO J B, AHLENIUS H, et al. Generation of oligodendroglial cells by direct lineage conversion[J]. Nat Biotechnol, 2013, 31(5):434-439.
[34] KIM J B, LEE H, ARAUZO-BRAVO M J, et al. Oct4-induced oligodendrocyte progenitor cells enhance functional recovery in spinal cord injury model[J]. EMBO J, 2015, 34(23):2971-2983.

Funding

Key Project of National Natural Science Foundation of China (No. 81230027); General Project of National Natural Science Foundation of China (No. 81471219); Outstanding Academic Leaders Planning of Shanghai Municipality (No. 14XD1403400)